Literature DB >> 6188771

Increased leukocyte histamine release with elevated cyclic AMP-phosphodiesterase activity in atopic dermatitis.

J M Butler, S C Chan, S Stevens, J M Hanifin.   

Abstract

Maximal leukocyte histamine release in response to concanavalin A was significantly higher in a group of 16 adult patients with moderate to severe atopic dermatitis when compared to 13 adult nonatopic, normal subjects. In a further four atopic dermatitis patients, histamine release was similar to that in the normal group suggesting the existence of "high-releaser" and "low-releaser" subsets within the atopic dermatitis group. Leukocyte cAMP phosphodiesterase activity was significantly higher in the high-releaser group than in the low-releaser and normal groups. High and low histamine release responses showed strong correlations with high and low phosphodiesterase activities. Pretreatment with the experimental cAMP phosphodiesterase inhibitor Ro-20-1724 in high releasers reduced the histamine release to normal levels. These findings suggest that increased histamine "releasability" in atopic dermatitis is related to abnormalities in cyclic nucleotide regulation. Basophil percentages within the leukocyte preparation and the histamine content per basophil were not significantly different between the atopics and normals. Histamine release did not correlate significantly with serum IgE levels.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6188771     DOI: 10.1016/0091-6749(83)90467-0

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  13 in total

Review 1.  The spectrum of cutaneous patch-test reactions in patients with atopic dermatitis.

Authors:  J M Hanifin; P A Klas
Journal:  Clin Rev Allergy Immunol       Date:  1996       Impact factor: 8.667

2.  Differential effect of phosphodiesterase 4 inhibitors on the proliferation of human peripheral blood mononuclear cells from normals and subjects with atopic dermatitis.

Authors:  K H Banner; N M Roberts; C P Page
Journal:  Br J Pharmacol       Date:  1995-12       Impact factor: 8.739

Review 3.  Pharmacophysiology of atopic dermatitis.

Authors:  J M Hanifin
Journal:  Clin Rev Allergy       Date:  1986-02

Review 4.  Phosphodiesterase 4 Inhibitor Therapies for Atopic Dermatitis: Progress and Outlook.

Authors:  Jusleen Ahluwalia; Jeremy Udkoff; Andrea Waldman; Jenna Borok; Lawrence F Eichenfield
Journal:  Drugs       Date:  2017-09       Impact factor: 9.546

Review 5.  Recent advances in treatment strategies for atopic dermatitis.

Authors:  Thomas Christian Roos; Stefan Geuer; Sabine Roos; Harald Brost
Journal:  Drugs       Date:  2004       Impact factor: 9.546

6.  Effects of theophylline and rolipram on leukotriene C4 (LTC4) synthesis and chemotaxis of human eosinophils from normal and atopic subjects.

Authors:  H Tenor; A Hatzelmann; M K Church; C Schudt; J K Shute
Journal:  Br J Pharmacol       Date:  1996-08       Impact factor: 8.739

Review 7.  Recent contributions to knowledge of the mechanism of action of nimesulide.

Authors:  M Bevilacqua; E Magni
Journal:  Drugs       Date:  1993       Impact factor: 9.546

Review 8.  Revisiting Therapies for Atopic Dermatitis that Failed Clinical Trials.

Authors:  Gaurav Agnihotri; Peter A Lio
Journal:  Clin Drug Investig       Date:  2020-05       Impact factor: 2.859

9.  Delineating the role of histamine-1- and -4-receptors in a mouse model of Th2-dependent antigen-specific skin inflammation.

Authors:  Subhashree Mahapatra; Melanie Albrecht; Barbara Behrens; Adan Jirmo; Georg Behrens; Christina Hartwig; Detlef Neumann; Ulrike Raap; Heike Bähre; Christina Herrick; Anna-Maria Dittrich
Journal:  PLoS One       Date:  2014-02-04       Impact factor: 3.240

Review 10.  Phosphodiesterase 4-targeted treatments for autoimmune diseases.

Authors:  Neal Kumar; Ari M Goldminz; Noori Kim; Alice B Gottlieb
Journal:  BMC Med       Date:  2013-04-04       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.